Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 5/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PLK4 | O00444 | 2/20 | 0.32 |
| ▸ | PAK4 | O96013 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442177 | 1.00 | NOS1 (0.36) | NOS1HTR2CHTR2AXDHRET | |
| SCHEMBL24348557 | 0.77 | PLK4 (0.38) | NOS1HTR2CHTR2AXDHRET | |
| SCHEMBL22554143 | 0.77 | PLK4 (0.41) | NOS1XDHRETPI4KALRRK2 | |
| SCHEMBL24348567 | 0.72 | JAK2 (0.36) | NOS1HTR2ACDK2MAPK1ALDH1A1 | |
| SCHEMBL24809820 | 0.69 | DYRK1A (0.37) | RETLRRK2PAK4MAPK1ADORA2A | |
| SCHEMBL30406140 | 0.67 | HTR2C (0.37) | HTR2CHTR2AXDHRETPI4KA | |
| SCHEMBL24348566 | 0.67 | HTR2C (0.37) | HTR2CHTR2AXDHRETPI4KA | |
| SCHEMBL20093432 | 0.64 | HTR2C (0.41) | HTR2CHTR2AXDHCCNA2CDK2 | |
| SCHEMBL290117 | 0.64 | NOS1 (0.47) | NOS1XDHRETPI4KALRRK2 | |
| SCHEMBL13692758 | 0.64 | NOS1 (0.52) | NOS1CDK2MAPK1HTTMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4688771-A1 | NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | REPARE THERAPEUTICS INC. (CA) | 2025-04-01 | — | — | US | disclosed |
| CN-114174292-B | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors | 修复治疗公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| CN-114174292-A | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors | 修复治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-113454080-A | Compounds, pharmaceutical compositions and methods of making compounds and methods of use thereof | 修复治疗公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | CTTN, SRC, PTK2 | NOS1 4286/4885HTR2C 1652/4885HTR2A 1542/4885 |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | NOS1 4066/4885HTR2C 4048/4885HTR2A 3936/4885 |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | NOS1 3866/4885HTR2C 3700/4885HTR2A 3436/4885 |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | ATR, CHEK2, CHEK1 | NOS1 4066/4885HTR2C 4048/4885HTR2A 3936/4885 |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | NOS1 4066/4885HTR2C 4048/4885HTR2A 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.